Stock Price Quote

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE2297.35-35.65 (-1.53 %)
PREV CLOSE ( ) 2333.00
OPEN PRICE ( ) 2374.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 32233
TODAY'S LOW / HIGH ( )2253.05 2374.75
52 WK LOW / HIGH ( )1240.75 2374.75
NSE2300.75-35.6 (-1.52 %)
PREV CLOSE( ) 2336.35
OPEN PRICE ( ) 2350.00
BID PRICE (QTY) 2300.75 (48107)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1579684
TODAY'S LOW / HIGH( ) 2253.00 2350.55
52 WK LOW / HIGH ( )1242 2366.35
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1991
Management Info
Ramesh Juneja - Chairman Rajeev Juneja - Managing Director
Registered Office

Address 208,Okhla Industrial Estate,Phase - 111,
New Delhi,
Delhi-110020

Phone 011-46846700

Email investors@mankindpharma.com

Website www.mankindpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

14Mar Mankind Pharma informs about investor
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
12Mar Rail Vikas Nigam, NBCC and Mankind Pha
Rail Vikas Nigam has emerged as the Lowest Bidder (L1) from Central Rail..
12Mar Mankind Pharma inches up on inking pac
Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or..
11Mar Mankind Pharma inks pact with AstraZen
Mankind Pharma has entered into an agreement with AstraZeneca Pharma Ind..
11Mar Mankind Pharma informs about press rel
Mankind Pharma has informed that Mankind Pharma & AstraZeneca Pharma..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit4870.7412482.57
Gross Profit 5763.52 15628.36
Operating Profit 6703.418601.64
Net Sales 23585.6681271.53

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

PROMOTERS 76.51%
MUTUAL FUNDS/UTI 7.55%
NON-INSTITUTION 6.97%
FI/BANKS/INSURANCE 1.94%
GOVERNMENT 0%
FII 0%

About Mankind Pharma Ltd.

Mankind Pharma Ltd. was incorporated in the year 1991. Its today's share price is 2297.35. Its current market capitalisation stands at Rs 92029.19 Cr. In the latest quarter, company has reported Gross Sales of Rs. 84716.97 Cr and Total Income of Rs.82899.36 Cr. The company's management includes Pradeep Chugh, Vivek Kalra, Bharat Anand, Vijaya Sampath, T P Ostwal, Surendra Lunia, Satish Kumar Sharma, Sheetal Arora, Rajeev Juneja, Ramesh Juneja.

It is listed on the BSE with a BSE Code of 543904 , NSE with an NSE Symbol of MANKIND and ISIN of INE634S01028. It's Registered office is at 208,Okhla Industrial Estate,Phase - 111New Delhi-110020, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhagi Bhardwaj Gaur & Co, Deloitte Haskins & Sells LLP, Goel Gaurav & Co, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.